Enrique Grande, MD, discusses the rationale of the IMvigor130 trial in urothelial cancer.
Enrique Grande, MD
Advertisement
Articles by Enrique Grande, MD
Enrique Grande, MD, discusses the design of the phase III IMvigor130 trial, which compared atezolizumab plus chemotherapy versus atezolizumab monotherapy (arm B) versus standard chemotherapy plus placebo in patients with previously untreated locally advanced or metastatic urothelial carcinoma.
Advertisement
Latest Updated Articles
Dr. Grande on the IMvigor130 Trial in Metastatic Urothelial CancerPublished: October 17th 2019 | Updated:
Dr. Grande on the Rationale of the IMvigor130 Trial in Urothelial CancerPublished: December 7th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5